We’re delighted to share that MyCural has been granted a patent in the US!
This achievement marks a significant milestone for MyCural in our mission to develop potential candidate drugs targeting the MYC oncoprotein, getting us closer to our final goal: a new cancer therapy for patients with aggressive, resistant, metastasized high-risk tumors, providing hope for those facing incurable cancer.
We’re immensely proud of our team’s hard work and dedication that made this possible. This milestone opens up new avenues for international growth, which will be a cornerstone for a quick transfer to clinics.
Thank you to everyone who has been part of this journey with us! Stay tuned for more updates!
